Nelarabine (Arranon)

From - A Hematology Oncology Wiki
Jump to navigation Jump to search

General information

Class/mechanism: Purine analog, antimetabolite. Nelarabine is metabolized to the cytotoxic deoxyguanosine analog, 9-β-Darabinofuranosylguanine (ara-G), which is eventually converted to ara-GTP. ara-GTP is incorporated into DNA and leads to inhibition of DNA synthesis and cell death.[1][2]
Route: IV
Extravasation: neutral

For conciseness and simplicity, currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the prescribing information.[1]

Diseases for which it is used

Patient drug information

History of changes in FDA indication

History of changes in EMA indication

  • 2007-08-22: Initial authorization as Atriance

History of changes in Health Canada indication

History of changes in PMDA indication

Also known as

  • Code name: 506U78
  • Brand names: Arranon, Atriance